Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
Alterity Therapeutics announced a virtual event featuring key opinion leaders to discuss insights on their lead drug candidate ATH434 for Multiple System Atrophy (MSA). The company will review Phase 2 clinical trial results demonstrating clinical efficacy and provide a high-level overview of the planned Phase 3 pivotal trial. The event aims to info…